Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review

Neoadjuvant chemotherapy (NAC) is often used to treat locally advanced disease for tumor downstaging, thus improving the chances of breast-conserving surgery. From the NAC response, it is possible to obtain prognostic information as patients may reach a pathological complete response (pCR). Those wh...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ana Julia Aguiar de Freitas, Rhafaela Lima Causin, Muriele Bertagna Varuzza, Cassio Murilo Trovo Hidalgo Filho, Vinicius Duval da Silva, Cristiano de Pádua Souza, Márcia Maria Chiquitelli Marques
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
Acceso en línea:https://doaj.org/article/1f0be989ac644ef1b055811f264ef492
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:1f0be989ac644ef1b055811f264ef492
record_format dspace
spelling oai:doaj.org-article:1f0be989ac644ef1b055811f264ef4922021-11-11T15:33:38ZMolecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review10.3390/cancers132154772072-6694https://doaj.org/article/1f0be989ac644ef1b055811f264ef4922021-10-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5477https://doaj.org/toc/2072-6694Neoadjuvant chemotherapy (NAC) is often used to treat locally advanced disease for tumor downstaging, thus improving the chances of breast-conserving surgery. From the NAC response, it is possible to obtain prognostic information as patients may reach a pathological complete response (pCR). Those who do might have significant advantages in terms of survival rates. Breast cancer (BC) is a heterogeneous disease that requires personalized treatment strategies. The development of targeted therapies depends on identifying biomarkers that can be used to assess treatment efficacy as well as the discovery of new and more accurate therapeutic agents. With the development of new “OMICS” technologies, i.e., genomics, transcriptomics, and proteomics, among others, the discovery of new biomarkers is increasingly being used in the context of clinical practice, bringing us closer to personalized management of BC treatment. The aim of this review is to compile the main biomarkers that predict pCR in BC after NAC.Ana Julia Aguiar de FreitasRhafaela Lima CausinMuriele Bertagna VaruzzaCassio Murilo Trovo Hidalgo FilhoVinicius Duval da SilvaCristiano de Pádua SouzaMárcia Maria Chiquitelli MarquesMDPI AGarticlepathological complete responseneoadjuvant chemotherapybreast cancermolecular biomarkersNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5477, p 5477 (2021)
institution DOAJ
collection DOAJ
language EN
topic pathological complete response
neoadjuvant chemotherapy
breast cancer
molecular biomarkers
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
spellingShingle pathological complete response
neoadjuvant chemotherapy
breast cancer
molecular biomarkers
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Ana Julia Aguiar de Freitas
Rhafaela Lima Causin
Muriele Bertagna Varuzza
Cassio Murilo Trovo Hidalgo Filho
Vinicius Duval da Silva
Cristiano de Pádua Souza
Márcia Maria Chiquitelli Marques
Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review
description Neoadjuvant chemotherapy (NAC) is often used to treat locally advanced disease for tumor downstaging, thus improving the chances of breast-conserving surgery. From the NAC response, it is possible to obtain prognostic information as patients may reach a pathological complete response (pCR). Those who do might have significant advantages in terms of survival rates. Breast cancer (BC) is a heterogeneous disease that requires personalized treatment strategies. The development of targeted therapies depends on identifying biomarkers that can be used to assess treatment efficacy as well as the discovery of new and more accurate therapeutic agents. With the development of new “OMICS” technologies, i.e., genomics, transcriptomics, and proteomics, among others, the discovery of new biomarkers is increasingly being used in the context of clinical practice, bringing us closer to personalized management of BC treatment. The aim of this review is to compile the main biomarkers that predict pCR in BC after NAC.
format article
author Ana Julia Aguiar de Freitas
Rhafaela Lima Causin
Muriele Bertagna Varuzza
Cassio Murilo Trovo Hidalgo Filho
Vinicius Duval da Silva
Cristiano de Pádua Souza
Márcia Maria Chiquitelli Marques
author_facet Ana Julia Aguiar de Freitas
Rhafaela Lima Causin
Muriele Bertagna Varuzza
Cassio Murilo Trovo Hidalgo Filho
Vinicius Duval da Silva
Cristiano de Pádua Souza
Márcia Maria Chiquitelli Marques
author_sort Ana Julia Aguiar de Freitas
title Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review
title_short Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review
title_full Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review
title_fullStr Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review
title_full_unstemmed Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review
title_sort molecular biomarkers predict pathological complete response of neoadjuvant chemotherapy in breast cancer patients: review
publisher MDPI AG
publishDate 2021
url https://doaj.org/article/1f0be989ac644ef1b055811f264ef492
work_keys_str_mv AT anajuliaaguiardefreitas molecularbiomarkerspredictpathologicalcompleteresponseofneoadjuvantchemotherapyinbreastcancerpatientsreview
AT rhafaelalimacausin molecularbiomarkerspredictpathologicalcompleteresponseofneoadjuvantchemotherapyinbreastcancerpatientsreview
AT murielebertagnavaruzza molecularbiomarkerspredictpathologicalcompleteresponseofneoadjuvantchemotherapyinbreastcancerpatientsreview
AT cassiomurilotrovohidalgofilho molecularbiomarkerspredictpathologicalcompleteresponseofneoadjuvantchemotherapyinbreastcancerpatientsreview
AT viniciusduvaldasilva molecularbiomarkerspredictpathologicalcompleteresponseofneoadjuvantchemotherapyinbreastcancerpatientsreview
AT cristianodepaduasouza molecularbiomarkerspredictpathologicalcompleteresponseofneoadjuvantchemotherapyinbreastcancerpatientsreview
AT marciamariachiquitellimarques molecularbiomarkerspredictpathologicalcompleteresponseofneoadjuvantchemotherapyinbreastcancerpatientsreview
_version_ 1718435164656238592